Advancing therapy with
iGlarLixi
versus premix BIAsp 30 in basal insulin‐treated type 2 diabetes: Design and baseline characteristics of the
SoliMix
randomized controlled trial
2019 ◽
Vol 21
(10)
◽
pp. 2327-2332
◽
2016 ◽
Vol 18
(4)
◽
pp. 366-374
◽
2004 ◽
Vol 27
(4)
◽
pp. 259-266
◽
2019 ◽
Vol 43
(7)
◽
pp. 477-482
◽
2017 ◽
Vol 9
(1)
◽
pp. 119-126
◽
2018 ◽
Vol 103
(6)
◽
pp. 2291-2301
◽
Keyword(s):